Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05635045 · ClinicalTrials.gov registry record · Phase 2
Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT05635045 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 10 participants.
The verdict
NCT05635045, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since their original 124I-evuzamitide PET scan. Ten previously scanned subjects re-consented to undergo another 124I-evuzamitide PET scan. Demographic, clinical and phenotypic data were collected to characterize potential changes since their previous scans.
Interventions
- DRUG I 124-Evuzamitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-07-08 |
| Est. Completion | 2024-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05635045
The ClinicalTrials.gov registry entry for NCT05635045 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which I 124-Evuzamitide is the first listed.
NCT05635045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05635045 about?
NCT05635045 is a clinical study titled "Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR". This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since their original 124I-evuzamitide PET scan. Ten previously scanned subjects ...
What is the current status of trial NCT05635045?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2022-07-08. Estimated completion is 2024-06-12.
What interventions are being tested in trial NCT05635045?
The interventions under investigation include: I 124-Evuzamitide (DRUG).
Who is sponsoring clinical trial NCT05635045?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.